PENHealthcare · Medical DevicesThe 17 Wall Street analysts covering Penumbra, Inc. hold a median 12-month price target of $374 — +16.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 3 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Penumbra, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (98): The share price has been relatively steady.
Revisions (45): Analysts have, on balance, been cutting their forecasts.
Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PEN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +16.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $335 → $320 |
| 11 June 2026 | RBC Capital | Reiterates | Sector Perform | — |
| 7 May 2026 | Citigroup | Maintains | Neutral | — |
| 7 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 26 Feb 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 20 Jan 2026 | Canaccord Genuity | Downgrade | Hold | — |
| 20 Jan 2026 | RBC Capital | Downgrade | Sector Perform | — |
| 16 Jan 2026 | Baird | Downgrade | Neutral | — |
| 16 Jan 2026 | BTIG | Downgrade | Neutral | — |
| 16 Jan 2026 | Citigroup | Downgrade | Neutral | — |
| 16 Jan 2026 | Jefferies | Downgrade | Hold | — |
| 16 Jan 2026 | Leerink Partners | Downgrade | Market Perform | — |
| 16 Jan 2026 | Needham | Downgrade | Hold | — |
| 16 Jan 2026 | Truist Securities | Downgrade | Hold | — |
| 15 Jan 2026 | Wells Fargo | Downgrade | Equal-Weight | — |
| 15 Jan 2026 | William Blair | Downgrade | Market Perform | — |
| 5 Jan 2026 | B of A Securities | Maintains | Buy | — |
| 18 Dec 2025 | JP Morgan | Upgrade | Overweight | — |
| 18 Dec 2025 | Truist Securities | Maintains | Buy | — |
| 17 Dec 2025 | Canaccord Genuity | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PEN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Penumbra, Inc. returned +37.2% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 9% of US stocks
Cheaper than 16% of US stocks
Cheaper than 11% of US stocks
Cheaper than 4% of US stocks
Higher than 63% of US stocks
Higher than 28% of US stocks
Higher than 81% of US stocks
Higher than 68% of US stocks
Higher than 70% of US stocks
Higher than 65% of US stocks
Higher than 82% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Penumbra, Inc. has a market value of $12.7B and an enterprise value of $12.2B.
Revenue in the twelve months to 30 June 2026: $1.5B. The latest quarter grew 15.6% year on year.
Net income over the same four quarters: $160.6M, a 10.7% net margin.
Diluted earnings per share, trailing twelve months: $4.07.
Free cash flow in the twelve months to 30 June 2026: $215.9M.
Trailing P/E: 80.7×; forward P/E: 52.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Penumbra, Inc. employs 4,700 people — $320K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Penumbra, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Penumbra, Inc. reported financial results for the third quarter ended September 30, 2026.
Why it matters — The report provides PEN watchers with the company’s latest quarterly financial update.
Penumbra announced that the FDA cleared its Lightning computer assisted vacuum thrombectomy technology for treating deep vein thrombosis. The company cited the BOLT-DVT prospective, multicenter IDE trial, which reported that first-line CAVT use for DVT was safe and effective.
Why it matters — The clearance marks an additional treatment indication for Penumbra’s CAVT technology.
Penumbra announced a subset analysis of the STORM-PE randomized controlled trial, reporting a significant correlation between wearable-tracked daily step activity and performance on the clinical 6-minute walk test in patients with pulmonary embolism.
Why it matters — The findings offer evidence about how wearable activity data may reflect real-world functional recovery among patients treated with CAVT and anticoagulation or anticoagulation alone.
Zacks Investment Research published an article comparing Integra LifeSciences (IART) and Penumbra (PEN), both in the Medical - Instruments sector, to assess which stock currently offers better value for value investors.
Why it matters — Penumbra watchers would care because the piece evaluates PEN's relative value positioning against a sector peer, informing how the stock is viewed by value-oriented investors.
Zacks Investment Research published a comparison of Integra LifeSciences (IART) and Penumbra (PEN) in the Medical - Instruments sector, examining which of the two companies offers the better value for investors seeking undervalued stocks. The article evaluates the two companies side by side on value metrics.
Why it matters — PEN watchers would care because the piece positions Penumbra in a value-stock comparison against a peer, which could influence how investors assess its attractiveness.
The 17 Wall Street analysts covering Penumbra, Inc. have a median 12-month price target of $374, with estimates ranging from $320 to $374. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering Penumbra, Inc., 3 rate it a Buy, 14 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Penumbra, Inc. 76 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Penumbra, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies +16.0% from the last close, and Ticker Nerd's factor model ranks Penumbra, Inc. 76 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Penumbra, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $320 to $374 over the next 12 months.
Penumbra, Inc. returned +37.2% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Penumbra Inc. is a medical device company that designs, develops, manufactures, and markets products for interventional therapies in vascular and neurological care.
The most recent item we track (PRNewsWire, 29 Oct 2026): "Penumbra, Inc. Reports Third Quarter 2026 Financial Results". Penumbra, Inc. reported financial results for the third quarter ended September 30, 2026.
Penumbra Inc. is a medical device company that designs, develops, manufactures, and markets products for interventional therapies in vascular and neurological care. Its portfolio centers on thrombectomy systems used to remove blood clots, including solutions for peripheral and neurovascular applications, along with access devices, embolization technologies, and neurosurgical tools. The company’s products are used in acute care settings by hospitals and physicians to support treatment of conditions such as stroke, pulmonary embolism, deep vein thrombosis, aneurysms, and other vascular disorders. Penumbra Inc. serves healthcare providers in the United States and international markets, positioning itself as a specialist in minimally invasive devices for complex clot-removal and vascular intervention procedures. Founded in 2004 and headquartered in Alameda, California, Penumbra Inc. focuses on medical technologies that address critical and time-sensitive clinical needs.
CEO Mr. Adam Elsesser J.D. · 4,700 employees · United States · https://www.penumbrainc.com
